Association of COMT Val108/158met genotype with smoking cessation in a nicotine replacement therapy randomized trial

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 6, 2007, Pages 1065-1069

  Johnstone, Elaine C ^a   Elliot, Katherine M ^a   David, Sean P ^b   Murphy, Michael F G ^a   Walton, Robert T ^a,c   Munafò, Marcus R ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^c MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL 2 METHYLTRANSFERASE; DOPAMINE; GENE PRODUCT; METHIONINE; NICOTINE PATCH; PLACEBO; UNCLASSIFIED DRUG; VALINE; CATECHOL METHYLTRANSFERASE; NICOTINE; NICOTINIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SMOKING CESSATION; THERAPY EFFECT; TOBACCO DEPENDENCE; GENETIC POLYMORPHISM; GENETICS; INTRADERMAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADULT; CATECHOL O-METHYLTRANSFERASE; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; MALE; NICOTINE; NICOTINIC AGONISTS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SEX FACTORS; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 34250861376     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0936     Document Type: Article

References (38)

1. Proctor RN. Tobacco and the global lung cancer epidemic. Nat Rev Cancer 2001;1:82-6.
2. WHO. WHO framework convention on tobacco control. Geneva: WHO Press; 2003.
3. Hughes JR. Motivating and helping smokers to stop smoking. J Gen Intern Med 2003;18:1053-7.
4. Munafo MR, Clark T, Johnstone EC, Murphy M, Walton RT. The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res 2004;6:583-97.
5. Munafo MR, Lerman C, Niaura R, Shields AE, Swan GE. Smoking cessation treatment: pharmacogenetic assessment. Curr Opin Mol Ther 2005;7:202-8.
6. Munafo MR, Shields AE, Berrettini WH, Patterson F, Lerman C. Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics 2005;6:211-23.
7. Johnstone EC, Yudkin PL, Hey K, et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 2004;14:83-90.
8. Lerman C, Jepson C, Wileyto EP, et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 2006;31:231-42.
9. 40 Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 2004;4:184-92.
10. Munafo MR, Johnstone EC, Wileyto EP, Shields PG, Elliot KM, Lerman C. Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev 2006;15:398-400.
11. Yudkin P, Munafo MR, Hey K, et al. Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. Br Med J 2004;328:989-90.
12. Dahl JP, Jepson C, Levenson R, et al. Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence. Pharmacogenomics J 2006;6:194-9.
13. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF. Impact of CYP2A6 genotype on pretreatment smoking behavior and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 2006;11:400-9.
14. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993;18:247-91.
15. Berrettini WH, Wileyto EP, Epstein L, et al. Catechol-O- methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol Psychiatry 2007;61:111-8.
16. Colilla S, Lerman C, Shields PG, et al. Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet Genomics 2005;15:393-8.
17. Balfour DJ. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens. Nicotine Tob Res 2004;6:899-912.
18. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996;382:255-7.
19. Chen J, Lipska BK, Halim N, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004;75:807-21.
20. Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci 2003;23:2008-13.
21. Jonsson EG, Nothen MM, Grunhage F, et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999;4:290-6.
22. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996;6:243-50.
23. Shield AJ, Thomae BA, Eckloff BW, Wieben ED, Weinshilboum RM. Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol Psychiatry 2004;9:151-60.
24. Beuten J, Payne TJ, Ma JZ, Li MD. Significant association of catechol-O-methyltransferase (COMT) haplotypes with nicotine dependence in male and female smokers of two ethnic populations. Neuropsychopharmacology 2006;31:675-84.
25. McKinney EF, Walton RT, Yudkin P, et al. Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. Pharmacogenetics 2000;10:483-91.
26. David SP, Johnstone E, Griffiths SE, et al. No association between functional catechol O-methyl transferase 1947A>G polymorphism and smoking initiation, persistent smoking or smoking cessation. Pharmacogenetics 2002;12:265-8.
27. Redden DT, Shields PG, Epstein L, et al. Catechol-O-methyl- transferase functional polymorphism and nicotine dependence: an evaluation of nonreplicated results. Cancer Epidemiol Biomarkers Prev 2005;14:1384-9.
28. Ball P, Knuppen R, Haupt M, Breuer H. Interactions between estrogens and catechol amines. 3. Studies on the methylation of catechol estrogens, catechol amines and other catechols by the catechol-O-methyltransferases of human liver. J Clin Endocrinol Metab 1972;34:736-46.
29. Xie T, Ho SL, Ramsden D. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol 1999;56:31-8.
30. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999;39:19-52.
31. Munafo MR, Bradburn M, Bowes L, David SP. Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis. Nicotine Tob Res 2004;6:769-76.
32. Imperial Cancer Research Fund. Effectiveness of a nicotine patch in helping people stop smoking: results of a randomised trial in general practice. Br Med J 1993;306:1304-8.
33. Imperial Cancer Research Fund. Randomised trial of nicotine patches in general practice: results at one year. Br Med J 1994;308:1476-7.
34. Lerman C, Audrain J, Tercyak K, et al. Attention-deficit hyperactivity disorder (ADHD) symptoms and smoking patterns among participants in a smoking-cessation program. Nicotine Tob Res 2001;3:353-9.
35. Volkow ND, Fowler JS, Wang GJ, Goldstein RZ. Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. Neurobiol Learn Mem 2002;78:610-24.
36. Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 2004;74:1-58.
37. Flint J, Munafo MR. The endophenotype concept in psychiatric genetics. Psychol Med 2007;37:163-80.
38. Russell MA, Peto J, Patel UA. The classification of smoking by factorial structure of motives. J R Stat Soc 1974;137:313-46.